Stock-Based Compensation (Tables)
|
6 Months Ended |
Jan. 31, 2023 |
Share-Based Payment Arrangement [Abstract] |
|
Schedule of Stock Options |
The activity of stock options for the six months ended January 31, 2023 consisted of the following: | | | | | | | | | | | | | | | | | | | | | | | | | Outstanding Stock Options | | Weighted-Average Exercise Price | | Weighted-Average Remaining Contractual Term (in years) | | Aggregate Intrinsic Value | | | | | | | | | | (in thousands, except per share amounts) | Balance as of July 31, 2022 | 1,673 | | | $ | 11.81 | | | 2.5 | | $ | 240,286 | | | | | | | | | | Exercised | (224) | | | 9.20 | | | | | 29,977 | | Canceled, forfeited or expired | (5) | | | 7.61 | | | | | | Balance as of January 31, 2023 | 1,444 | | | $ | 12.24 | | | 2.1 | | $ | 161,644 | | Exercisable and expected to vest as of July 31, 2022 | 1,501 | | | $ | 10.78 | | | 2.4 | | $ | 216,539 | | Exercisable and expected to vest as of January 31, 2023 | 1,375 | | | $ | 11.60 | | | 2.1 | | $ | 154,769 | |
|
Schedule of Restricted Stock Units and Performance Stock Awards Activity |
The activity of restricted stock units ("RSUs") and performance stock awards ("PSAs") consisted of the following for the six months ended January 31, 2023: | | | | | | | | | | | | | | | | | | | Underlying Shares | | Weighted-Average Grant Date Fair Value | | Aggregate Intrinsic Value | | | | | | | | (in thousands, except per share data) | Balance as of July 31, 2022 | 7,388 | | | $ | 157.17 | | | $ | 1,145,526 | | Granted | 2,365 | | | 157.94 | | | | Vested | (1,666) | | | 150.83 | | | 254,957 | | Canceled or forfeited | (738) | | | 168.08 | | | | Balance as of January 31, 2023 | 7,349 | | | $ | 157.76 | | | $ | 912,413 | |
|
Schedule of ESPP Valuation Assumptions |
The fair value of the purchase right for the ESPP was estimated on the grant date using the Black-Scholes option-pricing model with the following assumptions: | | | | | | | | | | | | | Six Months Ended January 31, | | 2023 | | 2022 | | | | | | | Expected term (in years) | 0.5 -2.0 | | 0.5 - 2.0 | Expected stock price volatility | 62.4% - 75.9% | | 44.1% - 57.4% | Risk-free interest rate | 4.2% - 4.7% | | 0.1% - 0.7% | Dividend yield | 0.0% | | 0.0% |
|
Schedule of Allocation of Stock-based Compensation Expense |
The components of stock-based compensation expense recognized in the condensed consolidated statements of operations consisted of the following: | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended January 31, | | Six Months Ended January 31, | | 2023 | | 2022 | | 2023 | | 2022 | | | | | | | | | | (in thousands) | Cost of revenue | $ | 9,410 | | | $ | 5,481 | | | $ | 17,842 | | | $ | 10,467 | | Sales and marketing | 54,213 | | | 44,586 | | | 107,848 | | | 85,307 | | Research and development | 29,005 | | | 28,626 | | | 53,536 | | | 55,885 | | General and administrative | 17,110 | | | 20,295 | | | 35,685 | | | 37,232 | | Total | $ | 109,738 | | | $ | 98,988 | | | $ | 214,911 | | | $ | 188,891 | |
|